MG
NVCR icon

Michael Gelband’s NovoCure NVCR Stock Holding History

Michael Gelband’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-59,253
Closed -$646K – 1917
2026
Q1 		$646K Buy
+59,253
New +$740K 0.01% 1121
2025
Q4 		– Sell
-83,486
Closed -$1.08M – 1909
2025
Q3 		$1.08M Buy
+83,486
New +$1.12M 0.01% 942
2024
Q4 		– Sell
-415,113
Closed -$6.49M – 1890
2024
Q3 		$6.49M Buy
415,113
+338,808
+444% +$6.14M 0.04% 325
2024
Q2 		$1.31M Sell
76,305
-156,406
-67% -$2.75M 0.01% 931
2024
Q1 		$3.64M Buy
232,711
+50,472
+28% +$742K 0.03% 491
2023
Q4 		$2.72M Buy
182,239
+32,111
+21% +$430K 0.02% 488
2023
Q3 		$2.42M Buy
150,128
+138,666
+1,210% +$4M 0.02% 617
2023
Q2 		$476K Buy
+11,462
New +$712K ﹤0.01% 1382
2022
Q3 		– Sell
-33,303
Closed -$2.31M – 2166
2022
Q2 		$2.31M Buy
+33,303
New +$2.51M 0.03% 724
2022
Q1 		– Sell
-18,975
Closed -$1.43M – 2536
2021
Q4 		$1.43M Buy
18,975
+9,816
+107% +$985K 0.01% 899
2021
Q3 		$1.06M Buy
9,159
+4,234
+86% +$640K 0.01% 994
2021
Q2 		$1.09M Buy
+4,925
New +$958K 0.01% 965
2021
Q1 		– Sell
-29,054
Closed -$5.03M – 2454
2020
Q4 		$5.03M Sell
29,054
-28,335
-49% -$3.88M 0.05% 246
2020
Q3 		$6.39M Sell
57,389
-13,430
-19% -$1.07M 0.13% 145
2020
Q2 		$4.2M Buy
70,819
+51,663
+270% +$3.4M 0.11% 191
2020
Q1 		$1.29M Sell
19,156
-18,903
-50% -$1.49M 0.07% 255
2019
Q4 		$3.21M Buy
38,059
+29,202
+330% +$2.36M 0.06% 235
2019
Q3 		$662K Buy
+8,857
New +$708K 0.02% 537

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Michael Gelband's NVCR Position: Q2 2026 in Review

Michael Gelband sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 59,253 shares — an estimated $646K sold.

Michael Gelband first reported a position in NVCR in Q3 2019 and held it in 18 quarters. The position peaked at $6.49M in Q3 2024. 215 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Michael Gelband reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 59,253 NovoCure shares in Q2 2026, an estimated $646K.
  • Michael Gelband first reported a position in NovoCure in Q3 2019 and held it in 18 quarters.
  • Michael Gelband's NovoCure position peaked at $6.49M in Q3 2024.
  • 215 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.